This article first appeared on GuruFocus .
Release Date: February 11, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Biotricity Inc ( BTCY ) reported three consecutive quarters of positive net operating income and EBITDA, indicating strong financial performance.
-
The company is experiencing accelerated demand for its remote patient management solutions, driven by an aging population and staffing shortages.
-
Biotricity Inc ( BTCY ) has expanded its cardiac AI cloud platform, enhancing diagnostic accuracy and patient outcomes.
-
The company achieved a 10.2% increase in revenue for the third quarter compared to the prior year, reaching $4 million.
-
Gross profit improved by 17.6% to $3.3 million, with a gross profit percentage increase to 81.5% from 76.4% in the prior year.
Negative Points
-
Despite improvements, Biotricity Inc ( BTCY ) reported a net loss of $1.1 million for the fiscal three-month period ended December 31, 2025.
-
The company is still not fully profitable, although it is nearing profitability.
-
Operating expenses for the third quarter were $2.8 million, indicating ongoing costs that need to be managed.
-
The company reported a loss per share of $0.02, although this is an improvement from the previous year's $0.04 loss per share.
-
Biotricity Inc ( BTCY ) is still in the process of pursuing additional regulatory approvals internationally, which could delay market expansion.
Q & A Highlights
Q: Can you provide an overview of Biotricity's financial performance for the third quarter of fiscal 2026? A: Dr. Wahaz Al-S Sadiq, CEO: Biotricity achieved positive net operating income and EBITDA for the third consecutive quarter. Revenue increased by 10.2% to $4 million compared to the prior year, driven by strong market adoption of our subscription models and FDA-cleared cardiac monitoring devices. Gross profit improved by 17.6% to $3.3 million, with a gross profit margin of 81.5%. Operating expenses decreased by 4.2%, and the company achieved a positive EBITDA of $280,000.
Q: What are the key strategic initiatives Biotricity is focusing on for future growth? A: Dr. Wahaz Al-S Sadiq, CEO: Biotricity is focused on expanding its cardiac AI cloud platform, pursuing FDA clearance for new AI clinical models, and expanding international regulatory approvals. The company is also extending care beyond clinics with BioHeart, a consumer tool, and expanding sales of BioCorp Pro, a next-generation cardiac monitoring device. These initiatives aim to enhance diagnostic accuracy, improve patient outcomes, and increase clinical profitability.
Q: How is Biotricity addressing the demand for remote patient management solutions? A: Dr. Wahaz Al-S Sadiq, CEO: Biotricity is uniquely positioned to lead the transition from reactive care to proactive management with clinically superior technology, favorable reimbursement economics, and a scalable operating model. The company is expanding its digital ecosystem, with its digital health app growing significantly and supporting over 400,000 patients annually. This approach allows providers to serve more patients using existing resources while increasing revenue.
Q: What are the financial expectations for Biotricity in the coming quarters? A: Johnny Aniglou, CFO: Biotricity anticipates continued revenue growth due to the popularity of its flagship devices and expanding market penetration. The company expects to achieve profitability in the next quarter, with positive free cash flows for the last six consecutive quarters. The focus remains on advancing the commercialization of Biocor, Bioflux, and BioCare products, which are dedicated to chronic cardiac disease prevention and management.
Q: How is Biotricity leveraging AI and technology to improve operational efficiencies? A: Johnny Aniglou, CFO: Biotricity has improved its gross profit margin through the expansion of recurring technology fee revenue and efficiencies gained from proprietary AI. The company has strategically transformed its sales force to focus on longer sales cycles and larger accounts, including independent hospitals and GPO networks. These efforts, along with proactive cost management, have contributed to achieving positive free cash flows and setting the company on a path toward profitability.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
